Dotatate gallium Ga-68

Generic Name
Dotatate gallium Ga-68
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C65H87GaN14O19S2
CAS Number
1027785-90-5
Unique Ingredient Identifier
9L17Y0H71P
Background

Dotatate gallium (Ga-68) is a somatostatin-2 receptor analog which is radiolabeled with gallium 68 as a positron-emitting radioisotope. Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors. Dotatate gallium (Ga-68) explotes its ab...

Indication

Dotatate gallium 68 is one of the most prominent radiopharmaceuticals used in imaging with positron emission tomography. It binds to the somatostatin-2 receptor which is usually overexpressed in many neuroendocrine tumors in both adult and pediatric patients. The neuroendocrine tumors are bening or malignant tumors produced in the hormone producing cells of ...

Associated Conditions
Neuroendocrine Tumors
Associated Therapies
-
Clinical Trials
Related News
jnm.snmjournals.org
·

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in ...

Intrapatient intermetastatic heterogeneity (IIH) in metastatic castration-resistant prostate cancer (mCRPC) patients was studied using a triple-tracer PET imaging strategy. IIH was observed in 82.7% of patients, with 45.9% having at least one 18F-FDG-positive/68Ga-PSMA-negative lesion. Patients with IIH had shorter median overall survival. The study identified 12 different lesion imaging phenotypes, highlighting the need for further molecular characterization and personalized treatment strategies.

Related Clinical Trials:

3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy